Biosimilars Toolkit
The Biosimilars Council is committed to providing the best educational resources available on biosimilars. For your convenience, our team has built a Biosimilars Toolkit for your outreach efforts.
This toolkit contains a host of resources by the Biosimilars Council and its partners. These shareable resources explain what biosimilars are, why they are important, how they can improve patient access and how they can save the United States billions of dollars.
We encourage you to share this information on biosimilars with interested colleagues, individuals and organizations.
Top Biosimilars Resources
View the top resources on biosimilars, created and published by the Biosimilars Council.
Biosimilars Handbook
The Biosimilars Handbook is the premier resource for biosimilar education. Choose from four different tracks – medical professional, patient, insurer or policymaker – to learn how biosimilars and interchangeable biologic products can decrease costs and increase access to lifesaving medicines.
Biosimilars 101
Biosimilars, a more cost-effective option for many patients who rely on biologic treatments, are beginning to enter the market.
FDA Biosimilars Approvals
Find an up-to-date list of FDA approved biosimilars and launches.
2021 Generic and Biosimilar Medicines Savings Report
This annual report is produced by the Institute for Human Data Science (IQVIA), the standard-bearer for measuring data, pharmaceutical use and spending in the United States.
Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines
An analysis by Avalere Health for the Biosimilars Council finds that 1.2 million U.S. patients could gain access to biologics by 2025 as the result of biosimilar availability.
Interchangeability 101 – Biosimilars and Interchangeable Biologics
This white board video from the Biosimilars Council walks through the basics of interchangeability and why biosimilars and interchangeable biologics are more than acceptable replacements for brand biologics.
Fact Sheets, Infographics, and Video
View the top fact sheets, infographics and videos from the Biosimilars Council.
Fact Sheet
Biosimilars: A Safe & Effective Option for Patients
Fact Sheet
Biosimilars: Breaking Down Barriers to Patient Access
Infographic
Skyrocketing Drug Prices
Infographic
How a Biosimilar Reaches a Patient
Video
FDA Biosimilars Action Plan
Video
IGBA Biosimilars Video
Additional Resources by Stakeholder
Are you a patient, payer, medical professional or policymaker? Our team has curated content specifically for those requiring the most information on biosimilars. Choose a set of resources below, grouped by stakeholder.
For Patients
Infographic
Myths vs. Facts for Patients
Partner Resource
APhA’s Biosimilar Basics Pamphlet
Infographic
Breaking Down Barriers to Patient Access
Infographic
Biosimilars: A Safe & Effective Option for Patients
Partner Resource
Understanding Biologic and Biosimilar Drugs
Partner Resource
FDA Biosimilar Basics for Patients
For Payers
Infographic
Myths vs. Facts for Payers
Video
“Epic Opportunities” Panel Discussion with Industry Leaders
Partner Resource
Understanding Biologic and Biosimilar Drugs
Council Handbook
The New Frontier for Improved Access to Medicines
Whitepaper
Insulin Biosimilars
For Medical Professionals
Infographic
Myth vs. Facts for Medical Professionals
Partner Resource
Understanding Biologic and Biosimilar Drugs
Partner Resource
FDA Resources for Medical Professionals
Partner Resource
APhA’s Biosimilar Basics Pamphlet
Whitepaper
Insulin Biosimilars
For Policymakers
Infographic
Myth vs. Facts for Medical Policymakers
Video
Time to Pass the CREATES Act
Whitepaper
Breaking Through On Biosimilars
Partner Resource
Understanding Biologic and Biosimilar Drugs
Video
The Case for Generic Competition
Want to Get Social?
Feel free to use the below sample social media posts to share information on biosimilars or the Biosimilars Council.
Sample Twitter Posts:
- #Biosmilars are safe, effective and increase patient access to essential medicines. Check out the @BiosimsCouncil Handbook to learn more: http://bit.ly/biosimshandbook
- #Biosimilars could save the U.S. health care system over $250 billion in the next decade. Learn more with the @BiosimsCouncil: www.biosimilarscouncil.org
- Take a deep dive into all things #biosimilars with @BiosimsCouncil Handbook: http://bit.ly/biosimshandbook
Sample Facebook Posts:
- Biosimilars are safe, effective and increase patient access to essential medicines. Learn more at www.biosimilarscouncil.org
- Biosimilars could save the U.S. health care system over $250 billion in the next decade. Learn more from the Biosimilars Handbook: http://bit.ly/biosimshandbook
- New biosimilars could produce major cost savings for patients and the health care system. Learn more from the Biosimilars Handbook: http://bit.ly/biosimshandbook
Sample LinkedIn Posts:
- Biosimilars have comparative safety and efficacy as their biologic counterpart, at a lower cost to the patient. Learn more about the benefits of biosimilars from our handbook: http://bit.ly/biosimshandbook
- High standards for approval by the FDA ensure that patients and health care providers can rely on biosimilars when they go to market. Learn more about the approval process in our handbook: http://bit.ly/biosimshandbook
- The introduction of safe and effective biosimilar therapies into the markets around the world has been proven to reduce health care costs while at the same time delivering lifesaving treatments to patients in need. https://biosimilarscouncil.org
Stay in the Loop
Stay up to date on the latest information and developments in the biosimilars industry by following us on social media or signing up for our newsletter.
Suggest a New Resource
Do you have a suggestion or recommendation for a resource?
Sign Up for Our Monthly Newsletter
The Biosimilars Bulletin is our monthly newsletter round up of all new resources, articles and information from the last month.
Sign Up for Our Monthly Newsletter
The Biosimilars Bulletin is our monthly newsletter round up of all new resources, articles, and information from the last month.